With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.
CEPI will work with Samsung Biologics to establish a scalable, rapid manufacturing process for recombinant-protein vaccines.
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
Focusing on the establishment of Sino Biological‘s Center for Bioprocessing (C4B) in Houston, it highlights how the ...
THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...
Pichia pastoris has emerged as a central microbial host for recombinant protein production, offering a unique balance of rapid growth, capacity for post‐translational modifications, and ease of ...
News-Medical.Net on MSN
Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Giuliana Rancic
Chicago, IL – January 26, 2026 – Sino Biological US, Inc. , a global leader in recombinant proteins, antibodies, and CRO ...
The pre-Series A funding round was co-led by existing backer WaterBridge Ventures and Japanese VC firm Enrission India Capital Founded in 2019, Loopworm manufactures high-protein animal feeds from ...
Non-specific Endonuclease Market to reach US$ 726.6 Bn by 2036 at 6.5% CAGR, driven by rising biotechnology research, ...
According to MarketsandMarkets™, the Proteins & Protein Crystals Market is projected to grow from about USD 609.51 billion in ...
Antibodies are the number one immune cells that fight against infection and diseases. However, beyond their natural usage, biochemistry has devised several ways in which these antibodies can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results